Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer

Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) ("Evogene"), a pioneering computational chemistry company specializing in generative ...